Merck Wins Approval for Combined Fosamax Treatment

NEW YORK (Reuters) Apr 08 - Merck & Co. Inc. said on Friday that U.S. regulators have approved a new version of its Fosamax osteoporosis treatment.

Merck said the U.S. Food and Drug Administration approved Fosamax plus D, a single once-weekly tablet containing both Fosamax and vitamin D.

The new product significantly reduces the risk of hip and spine fractures from osteoporosis in post-menopausal women, the company said.

Updated 4-13-05